Selection of blockbuster announcements

1、$Country Garden Holdings (02007.HK) $It is proposed to issue corporate bonds of no more than 500 million yuan, which is still at the planning stage

Country Garden Holdings issued an unusual share price volatility announcement on the Hong Kong Stock Exchange confirming that he was not aware of any reason for the increase in the shares or any information that must be disclosed to avoid a false market in the securities of the Company and any inside information to be disclosed. According to relevant media reports, the Group will issue RMB bonds, and the company said that it intends to issue domestic corporate bonds with a face value of no more than 500 million yuan to professional investors in the near future. The issuance of corporate bonds is still at the planning stage.

2、$Xiansheng Pharmaceutical Co. (02096.HK) $Xinguan oral drug SIM0417 approved clinical trial

Xiansheng Pharmaceutical announced that on May 13, 2022, the anti-novel coronavirus candidate drug SIM0417, which the group cooperated with Shanghai Institute of Pharmaceutical Research and Wuhan virus Research Institute of the Chinese Academy of Sciences, has obtained a notice of approval for drug clinical trials issued by the State Drug Administration, which is intended to be used for post-exposure prevention and treatment of people who have been exposed to COVID-19-positive people.

3、$China Shenhua Energy (01088.HK) $Total electricity sales in April were 12.03 billion kilowatt hours, an increase of 5.2% over the same period last year

China Shenhua Energy released the main operating data for April 2022, in which the company produced 26.8 million tons of commercial coal, an increase of 6.3 percent over the same period last year; coal sales reached 36.8 million tons; total power generation reached 12.83 billion kilowatt-hours, up 5.6 percent from the same period last year; and total electricity sales increased by 5.2 percent over the same period last year.

4、$Junshi creature (01877.HK) $The fifth indication approved by triplizumab in China

On May 13th, according to the latest announcement on the official website of the State Drug Administration (NMPA), the application for new indications of PD-1 inhibitor tripril (Tuoyi) developed by Junshi has been approved. This is also the fifth indication approved by triprizumab in China, which is combined with platinum-containing chemotherapy in the treatment of locally advanced or metastatic esophageal squamous cell carcinoma.

5、$China Pacific Insurance (02601.HK) $The original premium income in the first four months was 173.23 billion yuan, an increase of 6.23% over the same period last year.

China Pacific Insurance announced that from January to April 2022, the company's subsidiary China Pacific Life Insurance Co., Ltd. accumulated original insurance business income of 111.579 billion yuan, an increase of 4.0% over the same period last year. China Pacific property Insurance Co., Ltd., a subsidiary of the company, accumulated original insurance business income of 61.651 billion yuan, an increase of 10.6% over the same period last year, and a total of 173.23 billion yuan, an increase of 6.23%.

IPO information

Yunkang Group (02325) is 1.35 times subscribed for its public offering and is expected to be listed on May 18.

AH股

Junshi Bio's application to issue A shares to specific targets in 01877 was accepted by the Shanghai Stock Exchange.

Tianjin Entrepreneurship Environmental Protection Co., Ltd. (01065) A-share subscription application approved by China Securities Regulatory Commission

Operation data

China Shenhua Energy (01088): total electricity sales in April increased by 5.2% over the same period last year, up 12.03 billion kWh.

China Pacific Insurance (02601): the original premium income in the first four months was 173.23 billion yuan, an increase of 6.23% over the same period last year.

China China Eastern Airlines Corp Ltd (00670) April passenger turnover fell 89.75% compared with the same period last year.

China Taiping (00966) the original premium income of 79.946 billion yuan from January to April decreased by 1.00% compared with the same period last year.

Electricity sales of China Resources Power Holdings (00836) affiliated Power Plant increased by 4.3% in the first four months of 2022.

CLP Holdings Limited (00002) electricity sales in Hong Kong rose 0.3% year-on-year to 6.84 billion kWh in the first quarter

Merger and acquisition and sale

NWS Group (00659): Goshawk Aviation plans to sell its interest in commercial aircraft leasing platform to SMBC AC for US $1.575 billion

Big news

Country Garden Holdings (02007) has changed his stock price and plans to issue no more than 500 million yuan of corporate bonds in the near future.

Xiansheng Pharmaceutical (02096) COVID-19 Oral SIM0417 approved Clinical trial

Qingdao Port (06198) plans to acquire 51% stake in Weihai Port Development with 984 million yuan.

Junshi Bio (01877): application for new indications for first-line treatment of esophageal squamous cell carcinoma with triplizumab combined with chemotherapy approved

Shisiyao Group (02005) racoxamide has been approved by the State Drug Administration to be registered as an API for use in listed preparations.

Aoneng Construction (01183) was awarded a construction and decoration project valued at 74.57 million patacas.

Repurchase cancellation

Innovation Qizhi (02121) intends to buy back shares for no more than HK $315 million

AIA Group Limited (01299) spent HK $163 million to buy back 2.205 million shares on May 16.

Haier Smart Home (06690) spent 83.393 million yuan to buy back 3.2464 million A shares on May 16.

Skyworth Group (00751) spent HK $14.273 million to buy back 3.334 million shares on May 16.

Liwen Paper (02314) spent HK $3.403 million to buy back 971000 shares on May 16.

Sunac Services (01516) spent HK $2.1611 million to buy back 592000 shares on May 16.

Standard Chartered PLC (02888) spent 11.555 million pounds to buy back 1.997 million shares on May 13.

Equity incentive

Minimally invasive Medical (00853) granted a total of 19.1203 million share options

Wuxi Biologics (02269) affiliated WuXi Vaccines granted a total of 46.656 million share options

Sino Biopharmaceutical (01177): the trustee further purchased 10 million shares

JS Global Lifestyle Company Limited (01691): the trustee purchased a total of 9.2635 million shares under the restricted share unit scheme

MGM China (02282) Grants 480000 share options